REDWOOD CITY, Calif.,
Sept. 15, 2011 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that Richard
King, President and Chief Executive Officer, will present at
two separate investor conferences in New
York City over the coming weeks as follows:
UBS Global Life Sciences Conference
Date: Tuesday, September 20th at 7:30 AM EST
Location: Grand Hyatt New York
Webcast link:
http://cc.talkpoint.com/ubsx001/091911a_im/?entity=109_C624HWQ
The Sixth Annual JMP Securities Healthcare Conference
Date: Wednesday, September 28th at 11:00 AM EST
Location: The St. Regis New York
Webcast link: http://wsw.com/webcast/jmp14/acrx/
Both presentations will be webcast live and can be accessed
through the links above. For those not available to listen to
the live broadcast, the presentations will be archived and
available through http://www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA,
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain. AcelRx's lead product candidate, the
ARX-01 Sufentanil NanoTab PCA System, which is in preparation for
Phase 3 clinical development, is designed to solve the problems
associated with post-operative intravenous patient-controlled
analgesia which has been shown to cause harm to patients following
surgery because of the side effects of morphine, the invasive IV
route of delivery and the inherent potential for programming and
delivery errors associated with the complexity of infusion pumps.
AcelRx has two additional product candidates which have completed
Phase 2 clinical development: ARX-02 for the treatment of cancer
breakthrough pain, and ARX-03 for providing mild sedation, anxiety
reduction and pain relief for patients undergoing painful
procedures in a physician's office. A fourth product candidate,
ARX-04, is a sufentanil product for the treatment of
moderate-to-severe acute pain that is expected to enter Phase 2
clinical development in the second half of 2011 under a grant from
the US Army Medical Research and Material Command.
SOURCE AcelRx Pharmaceuticals, Inc.